{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:52:56Z","timestamp":1776073976170,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Seventh Framework Programme","award":["278981"],"award-info":[{"award-number":["278981"]}]},{"name":"Horizon 2020","award":["754923"],"award-info":[{"award-number":["754923"]}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"crossref","award":["ILP-POR-2019-066"],"award-info":[{"award-number":["ILP-POR-2019-066"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science Foundation Ireland","award":["20\/FFP-P\/8884"],"award-info":[{"award-number":["20\/FFP-P\/8884"]}]},{"name":"The Ian Harty Charitable Trust"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39189-w","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:01:40Z","timestamp":1776070900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Valentina","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gift","family":"Nyamundanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"L\u00e4rkeryd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S.","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Venken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominiek","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Boeckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Betge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias P. A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Gaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk M.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice C.","family":"O\u2019Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Barat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rut","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Fender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bauke","family":"Ylstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"van Grieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipto","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darran P.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diether","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen H. M.","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anguraj","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette T.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"39189_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41698-025-01058-6","volume":"9","author":"T Liu","year":"2025","unstructured":"Liu, T. et al. Machine learning-driven multi-targeted drug discovery in colon cancer using biomarker signatures. NPJ Precis Oncol 9, 297. https:\/\/doi.org\/10.1038\/s41698-025-01058-6 (2025).","journal-title":"NPJ Precis Oncol"},{"key":"39189_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41598-024-84023-w","volume":"15","author":"F Bahrambanan","year":"2025","unstructured":"Bahrambanan, F. et al. The development of an efficient artificial intelligence-based classification approach for colorectal cancer response to radiochemotherapy: deep learning vs machine learning. Sci. Rep. 15, 62. https:\/\/doi.org\/10.1038\/s41598-024-84023-w (2025).","journal-title":"Sci. Rep."},{"key":"39189_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41540-025-00513-1","volume":"11","author":"C Li","year":"2025","unstructured":"Li, C., Wei, Y. & Lei, J. Quantitative cancer-immunity cycle modeling for predicting disease progression in advanced metastatic colorectal cancer. NPJ Syst Biol Appl 11, 33. https:\/\/doi.org\/10.1038\/s41540-025-00513-1 (2025).","journal-title":"NPJ Syst Biol Appl"},{"key":"39189_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102811","author":"G Nyamundanda","year":"2020","unstructured":"Nyamundanda, G., Eason, K., Guinney, J., Lord, C. J. & Sadanandam, A. A machine-learning tool concurrently models single omics and phenome data for functional subtyping and personalized cancer medicine. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12102811 (2020).","journal-title":"Cancers (Basel)"},{"key":"39189_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J Clin"},{"key":"39189_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan, E. et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72, 338\u2013344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736 (2023).","journal-title":"Gut"},{"key":"39189_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki, K. et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27, 1539\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdw206 (2016).","journal-title":"Ann Oncol"},{"key":"39189_CR8","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz, L. B. et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25, 4557\u20134561. https:\/\/doi.org\/10.1200\/JCO.2007.12.0949 (2007).","journal-title":"J Clin Oncol"},{"key":"39189_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691 (2004).","journal-title":"N Engl J Med"},{"key":"39189_CR10","doi-asserted-by":"publisher","first-page":"238146832110210","DOI":"10.1177\/23814683211021060","volume":"6","author":"RE Pataky","year":"2021","unstructured":"Pataky, R. E. et al. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy Pract 6, 23814683211021060. https:\/\/doi.org\/10.1177\/23814683211021060 (2021).","journal-title":"MDM Policy Pract"},{"key":"39189_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1470-2045(12)70231-0","volume":"13","author":"D Lambrechts","year":"2012","unstructured":"Lambrechts, D. et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13, 724\u2013733. https:\/\/doi.org\/10.1016\/S1470-2045(12)70231-0 (2012).","journal-title":"Lancet Oncol"},{"key":"39189_CR12","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider, B. P. et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26, 4672\u20134678. https:\/\/doi.org\/10.1200\/JCO.2008.16.1612 (2008).","journal-title":"J Clin Oncol"},{"key":"39189_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30, 2119\u20132127. https:\/\/doi.org\/10.1200\/JCO.2011.39.9824 (2012).","journal-title":"J Clin Oncol"},{"key":"39189_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10456-014-9438-1","volume":"17","author":"S de Haas","year":"2014","unstructured":"de Haas, S. et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17, 909\u2013920. https:\/\/doi.org\/10.1007\/s10456-014-9438-1 (2014).","journal-title":"Angiogenesis"},{"key":"39189_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","volume":"31","author":"D Lambrechts","year":"2013","unstructured":"Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P. & Scherer, S. J. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31, 1219\u20131230. https:\/\/doi.org\/10.1200\/JCO.2012.46.2762 (2013).","journal-title":"J Clin Oncol"},{"key":"39189_CR16","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2017.77.1782","volume":"36","author":"E van Dijk","year":"2018","unstructured":"van Dijk, E. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. J. Clin. Oncol. 36, 2052\u20132060. https:\/\/doi.org\/10.1200\/JCO.2017.77.1782 (2018).","journal-title":"J. Clin. Oncol."},{"key":"39189_CR17","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/s41467-018-06567-6","volume":"9","author":"D Smeets","year":"2018","unstructured":"Smeets, D. et al. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat Commun 9, 4112. https:\/\/doi.org\/10.1038\/s41467-018-06567-6 (2018).","journal-title":"Nat Commun"},{"key":"39189_CR18","unstructured":"ANGIOPREDICT Consortium. https:\/\/cordis.europa.eu\/project\/id\/278981 n.d."},{"key":"39189_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000449412","volume":"94","author":"J Betge","year":"2016","unstructured":"Betge, J. et al. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion 94, 129\u2013137. https:\/\/doi.org\/10.1159\/000449412 (2016).","journal-title":"Digestion"},{"key":"39189_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. https:\/\/doi.org\/10.1186\/gb-2011-12-4-r41 (2011).","journal-title":"Genome Biol."},{"key":"39189_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression Models and Life-Tables. J R Stat Soc Series B Stat Methodol 34, 187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x (1972).","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"39189_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou, H. & Hastie, T. Regularization and Variable Selection Via the Elastic Net. J R Stat Soc Series B Stat Methodol 67, 301\u2013320. https:\/\/doi.org\/10.1111\/j.1467-9868.2005.00503.x (2005).","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"39189_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349561","volume":"42","author":"J Tabernero","year":"2022","unstructured":"Tabernero, J., Ros, J. & \u00c9lez, E. The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book 42, 1\u201310. https:\/\/doi.org\/10.1200\/EDBK_349561 (2022).","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"39189_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16, 1306\u20131315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9 (2015).","journal-title":"Lancet Oncol"},{"key":"39189_CR25","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.1073\/pnas.0902232106","volume":"106","author":"M Sheffer","year":"2009","unstructured":"Sheffer, M. et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 106, 7131\u20137136. https:\/\/doi.org\/10.1073\/pnas.0902232106 (2009).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"39189_CR26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/modpathol.3800666","volume":"19","author":"M Poetsch","year":"2006","unstructured":"Poetsch, M. et al. Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer. Mod. Pathol. 19, 1462\u20131469. https:\/\/doi.org\/10.1038\/modpathol.3800666 (2006).","journal-title":"Mod. Pathol."},{"key":"39189_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1005510","volume":"4","author":"A Sucker","year":"2015","unstructured":"Sucker, A. & Paschen, A. Deciphering the genetic evolution of T-cell resistance in melanoma. Oncoimmunology 4, e1005510. https:\/\/doi.org\/10.1080\/2162402X.2015.1005510 (2015).","journal-title":"Oncoimmunology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39189-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:01:45Z","timestamp":1776070905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39189"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39189-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from each patient and the study was carried out in accordance with the relevant guidelines and regulations effective for the participating study centers. Specifically, ethical review and approval of health-related research studies which are not clinical trials of medicinal products for human use as defined in SI 190\/2004 was undertaken by the Research Ethics Committee of Beaumont Hospital, RCSI Hospital Group in Ireland. The study was approved by the Medical Ethics Commission of the Faculty of Medicine in Mannheim, Heidelberg University in Germany. The collection, storage, and use of archival tissue and patient data were performed in compliance with the Code for Proper Secondary Use of Human Tissue in The Netherlands (2011), developed by the standing committee of the FEDERA (FMWV Foundation, Chamber of Commerce, Rotterdam, 41055219,\u00a0\n                      \n                      \u00a0and\u00a0\n                      \n                      ) and the Commissie Regelgeving in Onderzoek (COREON), in close cooperation with BBMRI-NL and patient organisations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this work, the authors used ChatGPT to query for additional information, improve the readability and language of the manuscript. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"8843"}}